BJMO - volume 13, issue 8, december 2019
J. Blokken PhD, PharmD, Tom Feys MBA, MSc, K. Punie MD
The 2019 edition of the annual ESMO meeting proved to be a grand cru when it comes to breast cancer studies. In early triple negative breast cancer (TNBC), the KEYNOTE-522 trial demonstrated a significant improvement of pathological complete response rate with the addition of pembrolizumab to neoadjuvant chemotherapy, irrespective of PD-L1 status. In addition to this, the prognostic value of tumour-infiltrating lymphocytes was confirmed in a pooled analysis of patients with TNBC who did not received adjuvant chemotherapy. In the field of metastatic breast cancer, much attention went to overall survival data that were presented for the CDK4/6-inhibitors ribociclib and abemaciclib in combination with fulvestrant (MONALEESA-3, MONARCH 2). Interesting results of the phase III BROCADE3 trial were presented in which the addition of the PARP inhibitor veliparib to carboplatin and paclitaxel was evaluated in patients with advanced HER2-negative breast cancer and a germline BRCA mutation. Regarding checkpoint inhibitors in metastatic TNBC, a read-out of a phase III trial with pembrolizumab compared to standard chemotherapy in second- and third-line was presented, as well as important translational data on different immunohistochemical PD-L1 assays from IMpassion130. Finally, two oral presentations focused on the use of CDK4/6-inhibitors in different combination regimens in metastatic HER2-positive breast cancer (MonarcHER) and in TNBC.
Read moreBJMO - volume 13, issue 7, november 2019
Tom Feys MBA, MSc
From 7–10th of September, the 2019 World Conference on Lung Cancer (WCLC) again proved to be the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. The meeting attracted more than 7,000 specialists from more than 100 countries. In this highlight report ten top abstracts presented at the meeting will be discussed. For a more complete coverage of the meeting we refer to the congress website: https://wclc2019.iaslc.org.
(BELG J MED ONCOL 2019;13(7):309–13)
Read moreBJMO - volume 13, issue 7, november 2019
Tom Feys MBA, MSc
Overview of Belgian reimbursement news
(BELG J MED ONCOL 2019;13(7):317)
Read moreBJMO - volume 13, issue 5, august 2019
Tom Feys MBA, MSc, P. Vuylsteke MD
The highlights in gynecologic cancers from ASCO 2019 include data on the outcome of chemotherapy or PARP inhibitors as monotherapy or combination therapy in (elderly) patients with ovarian cancer, as well as results of immune checkpoint blockade in patients with advanced or recurrent endometrial cancer with or without a mismatch repair deficiency. Novel findings in (early-stage) cervical cancer include the efficacy and safety of neoadjuvant chemotherapy followed by surgery vs. chemoradiation, and of minimally invasive hysterectomy compared to open radical hysterectomy.
Read moreBJMO - volume 13, issue 3, may 2019
Tom Feys MBA, MSc, J. Beekwilder PhD
The 2019 annual American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium was held from February 14-16 in San Francisco. The Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) organised a post-ASCO GU regional tour during which the highlights of the 2019 ASCO GU meeting were discussed. This tour featured four different meetings in four locations in Belgium: Namur, Ghent, Nivelles and Paal. This summary will specifically report on the meeting held in Ghent during which prof. dr Piet Ost (Ghent University Hospital) and prof. dr Sylvie Rottey (Ghent University Hospital) gave a summary of the most important advances in the treatment of prostate, bladder and renal cancer.
(BELG J MED ONCOL 2019;13(3):109–114)
Read moreBJMO - volume 13, issue 3, may 2019
Tom Feys MBA, MSc
Overview of Belgian reimbursement news
(BELG J MED ONCOL 2019;13(3):115–116)
Read moreBJMO - volume 13, issue 2, march 2019
Tom Feys MBA, MSc
From the 4–8th of December, the San Antonio Riverwalk again formed the background of the most important breast cancer congress in the world. This report will summarise eight top stories presented during the 2018 San Antonio Breast Cancer Symposium (SABCS). For a more complete overview of studies presented at the meeting, we refer to the congress website www.sabcs.org.
(BELG J MED ONCOL 2019;13(2):66–71)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
